Earnings Releases·Oct 27, 2026, 8:00 AM ET

CTS Corporation — Third Quarter 2026 Earnings Summary

**Financial Performance:** Q3 2026 sales rose 5% year-over-year to $149.6 million, while net income increased to $17.8 million and diluted EPS grew to $0.61; adjusted gross margin expanded 330 basis points to 42.2%, and free cash flow reached $41.1 million.
**Guidance Revision:** The company raised its full-year 2026 sales guidance to $580-$590 million and adjusted diluted EPS guidance to $2.78-$2.88, citing continued market strength.
**Strategic Progress:** Diversified end-market sales now comprise 60% of total revenue, driven by a 7% year-over-year growth rate and the advancing Millar acquisition to expand medical market presence.
**Balance Sheet Strength:** Cash and cash equivalents increased to $143.9 million as of September 30, 2026, while long-term debt decreased to $55.0 million.